Abstract Details

Title Air- and Bone-Conducted Cervical and Ocular Vestibular-Evoked Myogenic Potentials in Patients with Superior Vestibular Neuritis

Topic Neuro-ophthalmology/Neuro-otology

Presentation(s) IN4 - (-)

Poster/Presentation
Number 007

Objective

Background There has been debate about the origin of the VEMP, especially the ocular VEMP (oVEMP) activated by ACS and BCV at different sites.

Design/Methods Using ACS and BCV stimuli, cVEMPs and oVEMPs were recorded in SVN patients (n=33) and normal controls (n = 45).

Results ACS induced cVEMPs revealed mostly normal (81.9%) whereas results of ACS induced oVEMPs showed high rates of abnormalities (82%). oVEMP by BCV at the mid-frontal (Fz) revealed high rates of abnormalities (62.5%) especially on the contralesional eye and none of them showed abnormality on the ipsilesional eye. cVEMPs and oVEMPs induced by BCV at the mastoid process revealed dissociated results. cVEMP to mastoid BCV showed low rates of abnormalities (31.2%) whereas oVEMP to mastoid BCV revealed high rates of abnormalities (75%).

Conclusions The oVEMP in response to ACS may be mediated by the superior vestibular nerve, probably due to an activation of the utricular receptors. The high rates of abnormalities in Fz BCV oVEMP also suggest a dependence on the intactness of the superior vestibular nerve afferents. The dissociations in the abnormalities of cVEMP and oVEMP induced by BCV at the mastoid in patients with VN selectively involving the superior vestibular nerve suggest that the origin of the vestibular nerve afferents of oVEMP to mastoid BCV differ from those of cVEMP to mastoid BCV. Therefore oVEMP to mastoid BCV also reflects functions of the superior vestibular nerve afferents and most likely the utricular function.

Authors/Disclosures
Oh Sun-Young, MD, PhD PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Teri Schreiner, MD, MPH, FAAN (University of Colorado/ Children's Hospital of Colorado)	The institution of Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CDC. Dr. Schreiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Schreiner has received research support from Roche Genentech.
	No disclosure on file

��ɫ��

��ɫ��